Biogenesis of Exosomes Laden with Metallic Silver-Copper Nanoparticles Liaised by Wheat Germ Agglutinin for Targeted Delivery of Therapeutics to Breast Cancer

Glycosylation in extracellular vesicles: Isolation, characterization, composition, analysis and clinical applications

This review provides a comprehensive overview of our understanding of the role that glycans play in the formation, loading and release of extracellular vesicles (EVs). The capture of EVs (typically with a size of 100-200 nm) is described, including approaches based on glycan recognition with glycan-based analysis offering highly sensitive detection of EVs. Furthermore, detailed information is provided about the use of EV glycans and glycan processing enzymes as potential biomarkers, therapeutic targets or tools applied for regenerative medicine. The review also provides a short introduction into advanced methods for the characterization of EVs, new insights into the biomolecular corona covering EVs and bioanalytical tools available for glycan analysis.

AgCu NP Formation by the Ag NP Catalysis of Cu Ions at Room Temperature and Their Antibacterial Efficacy: A Kinetic Study

Although a facile route to prepare AgCu nanoalloys (NAs) with enhanced antibacterial efficacy using Ag NP catalysis of Cu ions at elevated temperatures was previously developed, its detailed reaction process is still unclear due to the fast reaction process at higher temperatures. This work found that AgCu NAs can also be synthesized by the same process but at room temperature. AgCu NAs formation kinetics have been studied using UV-Visible spectra and Transmission Electron Microscopy (TEM), where formation includes Cu²⁺ deposition onto the Ag NP surface and Ag⁺ release, reduction, and agglomeration to form new Ag NPs; this is followed by a redistribution of the NA components and coalescence to form larger AgCu NPs. It is found that SPR absorption is linear with time early in the reaction, as expected for both pseudo-first-order (PFO) and pseudo-second-order (PSO) kinetics; neither model is followed subsequently due to contributions from newly formed Ag NPs and AgCu NAs. The antibacterial efficacy of the AgCu NAs thus formed was estimated, with a continuous increase over the whole alloying process, demonstrating the correlation of antibacterial efficacy with the extent of AgCu NA formation and Ag⁺ release.

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

Gefitinib has shown promising efficacy in the treatment of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). Molecular biomarkers for gefitinib metabolism-related lncRNAs have not yet been elucidated. Here, we downloaded relevant genes and matched them to relevant lncRNAs. We then used univariate, LASSO, and multivariate regression to screen for significant genes to construct prognostic models. We investigated TME and drug sensitivity by risk score data. All lncRNAs with differential expression were selected for GO/KEGG analysis. Imvigor210 cohort was used to validate the value of the prognostic model. Finally, we performed a stemness indices difference analysis. lncRNA-constructed prognostic models were significant in the high-risk and low-risk subgroups. Immune pathways were identified in both groups at low risk. The higher the risk score the greater the value of exclusion, MDSC, and CAF. PRRophetic algorithm screened a total of 58 compounds. In conclusion, the prognostic model we constructed can accurately predict OS in NSCLC patients. Two groups of low-risk immune pathways are beneficial to patients. Gefitinib metabolism was again validated to be related to cytochrome P450 and lipid metabolism. Finally, drugs that might be used to treat NSCLC patients were screened.

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine

Clinically, cancer drug therapy is still dominated by chemotherapy drugs. Although the emergence of targeted drugs has greatly improved the survival rate of patients with advanced cancer, drug resistance has always been a difficult problem in clinical cancer treatment. At the current level of medicine, most drugs cannot escape the fate of drug resistance. With the emergence and development of gene detection, liquid biopsy ctDNA technology, and single-cell sequencing technology, the molecular mechanism of tumor drug resistance has gradually emerged. Drugs can also be updated in response to drug resistance mechanisms and bring higher survival benefits. The use of new drugs often leads to new mechanisms of resistance. In this review, the multi-molecular mechanisms of drug resistance are introduced, and the overcoming of drug resistance is discussed from the perspective of the tumor microenvironment.